Cellectis S.A.
$3.08-30.00%($-1.32)
TickerSpark Score
51/100
65
Valuation
40
Profitability
55
Growth
64
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMVLF research report →
52-Week Range48% of range
Low $1.25
Current $3.08
High $5.04
Companywww.cellectis.com
Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
- CEO
- Andre Choulika
- IPO
- 2014
- Employees
- 216
- HQ
- Paris, FR
Price Chart
+146.40% · this period
Valuation
- Market Cap
- $222.76M
- P/E
- -5.54
- P/S
- 3.93
- P/B
- 6.22
- EV/EBITDA
- -7.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.86%
- Op Margin
- -69.23%
- Net Margin
- -98.69%
- ROE
- -80.61%
- ROIC
- -26.92%
Growth & Income
- Revenue
- $75.92M · 82.91%
- Net Income
- $-70,343,970 · -91.35%
- EPS
- $-0.70 · -70.73%
- Op Income
- $-42,000,532
- FCF YoY
- -330.32%
Performance & Tape
- 52W High
- $5.04
- 52W Low
- $1.25
- 50D MA
- $4.41
- 200D MA
- $3.39
- Beta
- 2.84
- Avg Volume
- 3
Get TickerSpark's AI analysis on CMVLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CMVLF Coverage
We haven't published any research on CMVLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMVLF Report →